Emergent Biosolutions (ER4) Stock Statistics & Valuation Metrics

Emergent Biosolutions has a market cap or net worth of CHF186.02M. The enterprise value is CHF879.71.

Emergent Biosolutions has ― shares outstanding. The number of shares has decreased by -2.65% in one year.

Emergent Biosolutions’s return on equity (ROE) is 0.10 and return on invested capital (ROIC) is 5.90%.

The current PE Ratio of Emergent Biosolutions is ―. Emergent Biosolutions’s PEG ratio is -0.10.

In the last 12 months, Emergent Biosolutions had revenue of 742.90M and earned 52.60M in profits. Earnings per share was 0.98.

In the last 12 months, operating cash flow was 25.40M and capital expenditures -11.80M, giving a free cash flow of 13.60M billion.

Emergent Biosolutions pays an annual dividend of ―, resulting in a dividend yield of ―

Emergent Biosolutions upcoming earnings date is Nov 11, 2026, TBA (Confirmed).

Emergent Biosolutions as a current ratio of 5.01, with Debt / Equity ratio of 170.42%

In the past 12 months, Emergent Biosolutions has paid 30.20M in taxes.

Emergent Biosolutions EV to EBITDA ratio is 4.28, with an EV/FCF ratio of 6.56.

Emergent Biosolutions has CHF139.70M in cash and marketable securities with CHF581.80M in debt, giving a net cash position of -CHF442.10M billion.

Gross margin is 49.40%, with operating margin of 14.83%, and net profit margin of 7.08%.

The average price target for Emergent Biosolutions is CHF8.09, which is 11.43% higher than the current price. The consensus rating is Moderate Buy